|Bid||11.48 x 800|
|Ask||11.49 x 3000|
|Day's Range||11.40 - 11.60|
|52 Week Range||5.50 - 14.90|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
While Fluidigm Corporation (NASDAQ:FLDM) shareholders are probably generally happy, the stock hasn't had particularly...
Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. We would like to do so because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors […]
The decision to retire $150 million in convertible debt caught the market off guard, but the business made progress on its long-term goals.
Fluidigm (FLDM) delivered earnings and revenue surprises of -40.00% and 4.25%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 44 cents per share. Losses, adjusted for one-time gains and costs, came to 14 cents per share. The company that makes equipment to ...
Masimo (MASI) obtains CE mark of the ANI module for the Masimo Root Patient Monitoring and Connectivity Hub, which is likely to strengthen its expanding Root platform.
Better-than-expected performance at mass cytometry market and higher revenues is likely to aid Fluidigm's (FLDM) in Q1 earnings. However, sluggishness in microfluidics market remains a dampener.
Fluidigm (FLDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In 2016 Chris Linthwaite was appointed CEO of Fluidigm Corporation (NASDAQ:FLDM). This report will, first, examine...
Despite strength in the VIT business, AngioDynamics (ANGO) exited third-quarter fiscal 2019 on a tepid note, with both earnings and revenues missing estimates.
Glaukos' (GKOS) strong pipeline is indicative of brighter prospects ahead. However, cutthroat competition in the medical-device industry is worrisome.
As drug giants AbbVie and Merck and biotech progenitor Genentech establish themselves in South San Francisco, a much smaller life sciences company has scored the top four floors of the new, high-profile Genesis South San Francisco along Highway 101.
Fluidigm Corp creates, manufactures, and markets technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon microfluidics and mass cytometry technologies. Fluidigm Corp had annual average EBITDA growth of 19.90% over the past ten years. Warning! GuruFocus has detected 7 Warning Signs with FLDM.
A caller during the Lightning Round of "Mad Money" Monday asked Jim Cramer about Fluidigm Corp. Let's check out the charts of Fluidigm, which makes microfluidic systems for the life science and agricultural biotechnology industries. In this daily bar chart of FLDM, below, we can see that prices have rallied nicely from the middle of June.